Location History:
- Loughborough, GB (2007 - 2012)
- Leicestershire, GB (2012)
Company Filing History:
5 out of 1,500 
1 out of 7 Years Active: 2007-2012
Title: Innovations by Rhonan Lee Ford in the Field of Pharmaceutical Sciences
Introduction
Rhonan Lee Ford, an accomplished inventor based in Loughborough, GB, has made significant contributions to the field of pharmaceutical sciences. With a portfolio of five patents, his work is notably focused on developing compounds that target specific receptors for therapeutic applications.
Latest Patents
Ford's latest innovations include two patents concentrating on muscarinic M3 receptor antagonists. The first patent features quinuclidine derivatives designed to provide pharmaceutical compositions aimed at treating conditions mediated by M3 muscarinic receptors, specifically chronic obstructive pulmonary disease. The disclosed compounds demonstrate promising applications in therapy for such medical conditions.
The second patent focuses on quinuclidine derivatives of (hetero)arylciloheptanecarboxylic acid as muscarinic receptor antagonists. This invention outlines a group of specified compounds along with their preparation processes and applications in therapeutic settings. Both patents indicate Ford's commitment to advancing medical treatments through innovative chemical compounds.
Career Highlights
Throughout his career, Rhonan Lee Ford has been associated with leading companies in the pharmaceutical sector, including AstraZeneca and Pulmagen Therapeutics Limited. His experiences in these organizations have honed his skills in drug development and innovation, allowing him to make impactful contributions to the field.
Collaborations
In his professional journey, Ford has collaborated with esteemed colleagues such as Antonio Mete and Andrew Mather. Their collective expertise in pharmaceutical sciences has likely propelled joint efforts in researching and developing new therapeutic solutions, further enhancing the impact of Ford's work.
Conclusion
Rhonan Lee Ford's inventive contributions, particularly in the realm of muscarinic M3 receptor antagonists, reflect a strong commitment to improving health outcomes through innovative pharmacological solutions. His patents not only highlight his skills as an inventor but also underscore the importance of collaboration in driving forward the frontiers of medical science.